There is a clinical study on patients with liver cirrhosis undergoing radiofrequency ablation therapy. The subjects were divided into two groups, one group (25 people) took Aminoleban (BCAA) twice a day, and one group (26 people) Eat a normal diet. Through the long-term follow-up of these patients (average 3.9 years), it was found that the BCAA group had significantly lower complications, higher event-free survival, and lower intrahepatic recurrence. BCAA enteral nutrition may be beneficial to patients with liver cirrhosis after radiofrequency ablation, which can relieve mental stress and reduce the risk of intrahepatic recurrence and complications.
A clinical study of patients with malignant hepatocellular carcinoma showed that the incidence of refractory ascites was analyzed separately for the BCAA group (39 people) and the non-BCAA group (38 people), and there was no significant difference between the two groups. However, compared with the non-BCAA group, the frequency of refractory ascites and/or pleural effusion in the BCAA group was significantly lower. Moreover, in the preoperative oral BCAA group, the serum albumin concentration in the reduced state was higher than that in the non-BCAA group after liver (partial) resection. Although BCAA is not effective in preventing refractory ascites, it has been proven effective in improving serum albumin metabolism and preventing ascites and pleural effusion.
At present, BCAA is mainly used to treat hepatic encephalopathy and tardive dyskinesia in clinical practice, but there is no unified recommendation for the application of liver cancer in various countries. In clinical practice, evidence-based medicine should be used as the basis, through multidisciplinary cooperation such as gastroenterology, surgery, anesthesiology, and nutrition, to formulate a treatment plan suitable for patients.